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viduals not on antihypertensive therapy. Therefore, the
number needed to screen for albuminuria among individ-
uals not already receiving antihypertensive therapy is
significantly higher than that determined from NHANES
III. It is likely that more frequent use of antihypertensive
therapy has contributed to the lower prevalence of albu-
minuria in the Australian adult population of 1999 to
2000. These findings demonstrate the importance of con-
sidering concurrent use of interventions for the accurate
calculation of number needed to screen and consequent
assessment of effectiveness of screening.
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Reply from the Authors
We thank Drs. Briganti, Atkins, and Chadban for their
informative letter. As they mention, it is possible that
the differences in the prevalence of albuminuria between
the 1988 and 1994 American National Health and Nutri-
tion Examination Survey (NHANES) III [1] and the 1999–
2000 Australian AusDiab Kidney Study [2] result from
the increased use of antihypertensive therapy (supporting
the prediction we made in our paper). Differences be-
tween these studies may also relate to measurement tech-
niques, sampling methods, or population demographics. A
further consideration is whether the differences observed,
though statistically significant because of the large sample
size, are really clinically relevant. For example, in the
general population, the number needed to screen to iden-
tify one patient with an albumin to creatinine ratio greater
than 3.0 in AusDiab was 13 (95% confidence interval, 11
to 16), and in NHANES III was 11 (95% confidence
interval, 10 to 12).
The data provided by Briganti, Atkins, and Chadban
suggest that there are two methods by which secular in-
creases in antihypertensive therapy use (specifically, an-
giotensin-converting enzyme inhibitor and angiotensin re-
ceptor blocker use) may influence estimates of screening
effectiveness for prevention of end-stage renal disease
(ESRD); the number of patients who develop increased
serum creatinine or proteinuria may be reduced due to
effective therapy, and the number of patients in which
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management would change based on case finding through
screening may be reduced because patients are already
receiving effective therapy to reduce their risk of ESRD.
These considerations highlight the changing nature of evi-
dence and the difficulties in calculating the current effec-
tiveness of screening.
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